While only 20% of the drugs on the market today are biologics, it is expected that with 650 biotechnology medicines in development in 2010 for more than 100 diseases, half the new drugs approved in 2015 will be biologics and most of them will be monoclonal antibodies.
By attending this conference you will: - Gain insight on various therapeutic targets on oncology, multiple sclerosis, cardiovascular and autoimmune disorders
- Evaluate advances in antibody technology such as fragments, conjugates and multi-specific antibodies
- Learn about future of monoclonal antibody technology
- Hear about new antibody engineering and modification technologies
- Examine platform approaches to monoclonal antibody purification
- Find out new techniques in cell engineering for monoclonal antibody production
- Explore antibody-based targeted therapy: taking advantage of the human innate immunity
- Assess trends in capacity utilisation for therapeutic monoclonal antibody production
- Improve antibody production using directed evolution
- Investigate immunogenicity issues with drug development
- Identify suitable assays for evaluating the immunogenicity of mAbs
- Review contract production of mAbs for research and pre-clinical purposes
- Understand navigation strategies for intellectual property in the antibody world
- Review latest regulations, technologies, production methods and therapeutics
- Be part of a major networking opportunity
